Adverse Drug Reaction Classification System

         

ADR Ontology
ADR Term Polyneuropathy in malignant disease
ADR ID BADD_A10716
ADR Hierarchy
10      Immune system disorders
10.02      Immune disorders NEC
10.02.01      Immune and associated conditions NEC
10.02.01.100      Polyneuropathy in malignant disease
16      Neoplasms benign, malignant and unspecified (incl cysts and polyps)
16.32      Neoplasm related morbidities
16.32.01      Paraneoplastic syndromes NEC
16.32.01.014      Polyneuropathy in malignant disease
17      Nervous system disorders
17.09      Peripheral neuropathies
17.09.04      Chronic polyneuropathies
17.09.04.010      Polyneuropathy in malignant disease
Description A diffuse or multifocal peripheral neuropathy related to the remote effects of a neoplasm, most often carcinoma or lymphoma. Pathologically, there are inflammatory changes in peripheral nerves. The most common clinical presentation is a symmetric distal mixed sensorimotor polyneuropathy. (Adams et al., Principles of Neurology, 6th ed, p1334) [MeSH]
MedDRA Code 10036115
MeSH ID D020364
ADR Severity Grade (FAERS)
ADR Severity Grade (CTCAE) Not Available
Synonym
Carcinomatous neuropathy | Polyneuropathy in malignancy | Polyneuropathy in malignant disease | Paraneoplastic polyneuropathy | Paraneoplastic Polyneuropathy | Paraneoplastic Polyneuropathies | Polyneuropathies, Paraneoplastic | Paraneoplastic Neuropathy | Polyneuropathy, Paraneoplastic | Neuropathy, Paraneoplastic | Neuropathies, Paraneoplastic | Paraneoplastic Neuropathies | Paraneoplastic Peripheral Neuropathy | Neuropathies, Paraneoplastic Peripheral | Neuropathy, Paraneoplastic Peripheral | Paraneoplastic Peripheral Neuropathies | Peripheral Neuropathies, Paraneoplastic | Peripheral Neuropathy, Paraneoplastic
Drugs Leading to the ADR
Drug IDDrug NameADR Frequency (FAERS)ADR Severity Grade (FAERS)
BADD_D01253Lenalidomide0.000362%
The 1th Page    1    Total 1 Pages